• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Syneos Health Names Terttu Haring President, Clinical Sites & Patients

    9/26/23 7:30:00 AM ET
    $SYNH
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $SYNH alert in real time by email

    MORRISVILLE, N.C., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (NASDAQ:SYNH), a leading fully integrated biopharmaceutical solutions organization, has announced the appointment of Terttu Haring, MD, as President, Clinical Sites & Patients. With nearly 30 years of experience, Dr. Haring will lead the global clinical operations organization to drive exceptional delivery, quality and data integrity for customers, while ensuring a positive experience for sponsors, sites and patients. Her investigator background, and technology and data experience, will empower the Clinical Sites & Patients team to execute data-driven solutions that produce strong results for customers.

    Under Dr. Haring's guidance, Syneos Health will continue to nurture its heritage of scientific and therapeutic expertise across global clinical operations. Dr. Haring will also empower the Clinical Sites & Patients team to leverage the Company's in-depth local regulatory experience, with its expanding global footprint, to better connect patients and sites worldwide. Fueled by advanced data, analytics and insights from sources such as Syneos Health's Patient Voice Consortium, the team is leveraging technology and deep enterprise expertise to execute more representative clinical trial research.

    Based in Amsterdam, Netherlands, Dr. Haring's appointment adds to a growing team of global therapeutic experts at Syneos Health who design and execute fit-for-purpose solutions that deliver high-quality results for customers across the clinical to commercial continuum.

    "As the clinical trial landscape rapidly evolves, a steadfast focus on designing the best protocols, enabling sites and site networks, and empowering patients is key for successful clinical trial execution and product commercialization," said Michael Brooks, Chief Operating Officer, Syneos Health. "We are thrilled to welcome Terttu to our organization to help us advance our operating model to more effectively execute clinical operations that meet industry, customer, partner and patient needs. Her relentless focus on execution and quality will continue to build our patient-centered clinical trial solutions that enable sponsors to accelerate the development of treatments that impact patients' lives."

    With decades of pharma and CRO experience, Dr. Haring most recently held multiple leadership roles at Sanofi, with escalating responsibility across Clinical Research, Trial Operations and Data Management, and Clinical Innovation. She began her research career at Kendle International, a CRO acquired by INC Research, which then became Syneos Health.

    "I am passionate about unlocking the potential of clinical trials for all patients – leveraging digital health, data science and site productivity enhancements for optimized operations," said Dr. Haring. "I look forward to leveraging Syneos Health's vast enterprise to deliver for sponsors and bring patients and sites more actively together – meeting and anticipating the needs of all stakeholders in the clinical trial ecosystem."

    About Syneos Health

    Syneos Health® (NASDAQ:SYNH) is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. We translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities.  

    We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. 

    Together we share insights, use the latest technologies and apply advanced business practices to speed our customers' delivery of important therapies to patients. 

    Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.  

    To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com.

    Investor Relations Contact:   Press/Media Contact:
    Ronnie Speight    Gary Gatyas
    Senior Vice President, Investor Relations  Executive Director, External Communications
    +1 919 745 2745   +1 908 763 3428
    [email protected] [email protected] 

     



    Primary Logo

    Get the next $SYNH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SYNH

    DatePrice TargetRatingAnalyst
    2/13/2023$30.00 → $28.00Neutral → Underweight
    JP Morgan
    1/17/2023$30.00 → $25.00Overweight → Underweight
    Barclays
    1/13/2023$25.00Overweight → Underweight
    Barclays
    12/14/2022$66.00 → $38.00Buy → Neutral
    Mizuho
    11/7/2022$55.00 → $27.00Outperform → In-line
    Evercore ISI
    10/18/2022$85.00 → $53.00Overweight → Neutral
    JP Morgan
    9/14/2022Buy → Neutral
    Guggenheim
    9/7/2022$68.00Neutral
    UBS
    More analyst ratings

    $SYNH
    SEC Filings

    See more
    • SEC Form 15-12G filed by Syneos Health Inc.

      15-12G - Syneos Health, Inc. (0001610950) (Filer)

      10/10/23 6:08:58 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form 8-K filed by Syneos Health Inc.

      8-K - Syneos Health, Inc. (0001610950) (Filer)

      10/3/23 8:12:59 AM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care
    • SEC Form S-8 POS filed by Syneos Health Inc.

      S-8 POS - Syneos Health, Inc. (0001610950) (Filer)

      9/28/23 12:32:55 PM ET
      $SYNH
      Biotechnology: Commercial Physical & Biological Resarch
      Health Care